EPCAM and neoplasm: Notably, EpCAM-ReTARGTPRIFNαR149A significantly enhanced the cytotoxic capacity of PBMCs of donor #4, whereas EpCAM-ReTARGTPRvIL2 only marginally enhanced tumor cell lysis even at the highest PBMC:OvCAR3 (5:1) cell ratio (Figure 3B).